ArticleRMD open2022

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies.

Christopher T Ritchlin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.